Proposal No. **13-111**

Proposal for Task Force Consideration at the ISSC 2019 Biennial Meeting	. a. ☒ Growing Area b. ☐ Harvesting/Handling/Distribution c. ☐ Administrative

Submitter	David C. Deardorff
Affiliation	Abraxis LLC
Address Line 1	54 Steamwhistle Drive
Address Line 2	
City, State, Zip	Warminster, PA 18974
Phone	215-357-3911
Fax	215-357-5232
Email	ddeardorff@abraxiskits.com
Proposal Subject	DSP PPIA Kit for Determination of Okadaic Acid Toxins Group (OA, DTX1, DTX2) in Molluscan Shellfish
Specific NSSP Guide Reference	Section IV. Guidance Documents Chapter II. Growing Areas .11 Approved NSSP Laboratory Tests Marine Biotoxin Testing
Text of Proposal/ Requested Action	The DSP PPIA kit be approved as a Marine Biotoxin Laboratory Test Method.
Public Health Significance	Okadaic acid (OA) and its analogues, DTX1, DTX2, together with their ester forms are known as the group of OA-toxins. These toxins, lipophilic and heat stable, are produced by dinoflagellates and can be found in various species of shellfish, mainly in filter feeding bivalve molluscs. The OA-toxins group causes Diarrheic Shellfish Poisoning (DSP), which is characterized by symptoms such as diarrhea, nausea, vomiting and abdominal pain. These symptoms may occur in humans shortly after consumption of contaminated bivalve molluscs such as mussels, clams, scallops or oysters. Inhibition of serine/threonine phosphoprotein phosphatases is assumed to be responsible for these toxic effects. Recently in the Pacific Northwest harvest areas, outbreaks of DSP have occurred.
Cost Information	Refer to Para D.1. of the Checklist
Action by 2013 Laboratory Methods Review and Quality Assurance Committee	Recommended referral of Proposal 13-111 to an appropriate committee as determined by the Conference Chairman and directed the Executive Office send a letter to the submitter requesting additional information as provided by the Laboratory Methods Review and Quality Assurance Committee.
Action by 2013 Task Force I	Recommended adoption of Laboratory Methods Review and Quality Assurance Committee recommendation on Proposal 13-111.
Action by 2013 General Assembly	Adopted recommendation of 2013 Task Force I on Proposal 13-111.
Action by FDA May 5, 2014	Concurred with Conference action on Proposal 13-111.
Action by 2015 Laboratory Methods Review Committee	Recommended referral of Proposal 13-111 to an appropriate committee as determined by the Conference Chair until additional data are received.
Action by 2015 Task Force I	Recommended adoption of Laboratory Methods Review Committee recommendation on Proposal 13-111.
Action by 2015 General Assembly	Adopted the recommendation of Task Force I on Proposal 13-111.
Action by FDA January 11, 2016	Concurred with Conference action on Proposal 13-111.
Action by FDA	Concurred with Conference action on Proposal 13-111.

January 11, 2016	
Action by 2017 Laboratory Committee	Recommended referral of Proposal 13-111 to an appropriate committee as determined by the Conference Chair.
Action by 2017 Task Force I	Recommended adoption of Laboratory Committee recommendation on Proposal 13-111.
Action by 2017 General Assembly	Adopted the recommendation of Task Force I on Proposal 13-111.
Action by FDA February 7, 2018	Concurred with Conference action on Proposal 13-111.